scholarly journals Correlation assessment of gender and thyroid hormones in patients with primary oligomenorhea in anamnesis

2021 ◽  
Vol 38 (6) ◽  
pp. 52-58
Author(s):  
K. P. Ibadullaeva-Adygezalova

Objective. To determine the concentration of pituitary, ovarian and thyroid hormones in the blood and the correlation between them in women with a history of primary oligomenorrhea. Material and methods. The study involved 56 women of reproductive age with primary oligomenorrhea. Control 50 women of fertile age with an undisturbed rhythm of menstruation. An ultrasound of the uterus, ovaries and thyroid gland was performed. Concentrations of luteinizing hormone (LH), follicle stimulating hormone (FSH), prolactin, estradiol, testosterone dehydroepiandrosterone sulfate (DHEA-S), triiodothyronine (T3), thyroxine (T4), thyroid stimulating hormone (TSH) were determined by ELISA. Results. The average age of women in the main and control groups was 30.0 1.34 and 30.52 5.92 years (p 0.05), respectively. The average age of menarche in women of the main group was 13.27 0.80 years; duration of menstruation 3.4 0.40 days and 5.2 0.82 days (p = 0.051), respectively; duration of the menstrual cycle was 33.90 0.70 days (p = 0.001). Length and width of the uterus 3.99 0.19 cm (p = 0.055) and 4.51 0.11 cm, respectively; endometrial thickness 9.78 1.20 mm. The sizes of thyroid lobes did not differ between the groups. The LH level and the LH / FSH ratio were higher than the control values by 50.79 % (p = 0.052) and 52.66 % (p = 0.045), respectively. Testosterone and TSH concentrations were 38.33 and 34.36 % higher, respectively. The estradiol level was reduced by 56.67 % (p = 0.113). A weak correlation was revealed between sex and thyroid hormones. Conclusions. In women with a history of primary oligomenorrhea, the concentration of luteini-zing hormone and the LH / FSH ratio in the blood serum are significantly higher (p 0.05). In women with primary oligomenorrhea, there was a weak correlation between sex and thyroid hormones. The results will provide insight into the relationship between the thyroid function and the menstrual cycle.

2021 ◽  
Vol 53 (04) ◽  
pp. 272-279
Author(s):  
Chaochao Ma ◽  
Xiaoqi Li ◽  
Lixin Liu ◽  
Xinqi Cheng ◽  
Fang Xue ◽  
...  

AbstractThyroid hormone reference intervals are crucial for diagnosing and monitoring thyroid dysfunction during early pregnancy, and the dynamic change trend of thyroid hormones during pregnancy can assist clinicians to assess the thyroid function of pregnant women. This study aims to establish early pregnancy related thyroid hormones models and reference intervals for pregnant women. We established two derived databases: derived database* and derived database#. Reference individuals in database* were used to establish gestational age-specific reference intervals for thyroid hormones and early pregnancy related thyroid hormones models for pregnant women. Individuals in database# were apparently healthy non-pregnant women. The thyroid hormones levels of individuals in database# were compared with that of individuals in database* using nonparametric methods and the comparative confidence interval method. The differences in thyroid stimulating hormone and free thyroxine between early pregnant and non-pregnant women were statistically significant (p<0.0001). The reference intervals of thyroid stimulating hormone, free thyroxine and free triiodothyronine for early pregnant women were 0.052–3.393 μIU/ml, 1.01–1.54 ng/dl, and 2.51–3.66 pg/ml, respectively. Results concerning thyroid stimulating hormone and free thyroxine reference intervals of early pregnancy are comparable with those from other studies using the same detection platform. Early pregnancy related thyroid hormones models showed various change patterns with gestational age for thyroid hormones. Early pregnancy related thyroid hormones models and reference intervals for pregnant women were established, so as to provide accurate and reliable reference basis for the diagnosing and monitoring of maternal thyroid disfunction in early pregnancy.


2020 ◽  
Vol 6 (6) ◽  
pp. e290-e294
Author(s):  
Stephanie B. Lubchansky ◽  
Ruth McManus

Objective: Hirsutism and hyperandrogenism in premenopausal women are most often associated with polycystic ovarian syndrome. We present a case of progressive, severe hyperandrogenism with negative imaging identified on surgical histopathology as being due to a Leydig cell tumor (LCT), thus illustrating localization challenges associated with these small tumors. Methods: Laboratory investigations included testosterone, dehydroepiandrosterone sulfate, 17-hydroxyprogesterone, luteinizing hormone, follicle-stimulating hormone, thyroid-stimulating hormone, 24-hour urine cortisol, and prolactin. Imaging included pelvic ultrasound, adrenal magnetic resonance imaging, and computed tomography. Ovarian vein sampling was not available. Results: A 42-year-old woman presented with frontal alopecia, voice deepening, coarse facial hair, and amenorrhea on a background of lifelong oligomenorrhea. Peak testosterone was 30.2 nmol/L (female normal range is <2.0 nmol/L) with normal dehydroepiandrosterone sulfate, 17-hydroxyprogesterone, prolactin, 24-hour urine cortisol, and thyroid-stimulating hormone. Transvaginal ultrasound, adrenal magnetic resonance imaging, and computed tomography of the thorax and abdomen revealed no androgen source. Testosterone failed to suppress with gonadotropin-releasing hormone agonist. Although no abnormality was seen during oophorectomy, surgical pathology documented a 1.8-cm, well-circumscribed hilar LCT. Postoperative testosterone was <0.5 nmol/L. Conclusion: Although this patient had testosterone levels well into the masculine range, multiple imaging results were negative with a LCT found only after oophorectomy. LCTs are rare ovarian stromal tumors and while 50 to 70% of these tumors produce androgen, size and clinical severity may not be well correlated. This case report illustrates that despite an association with substantially elevated androgen levels, the small size of LCTs can result in localization challenges.


1999 ◽  
Vol 45 (12) ◽  
pp. 2207-2215 ◽  
Author(s):  
Brian Rafferty ◽  
Rose Gaines Das

Abstract Background: The increasing use of recombinant-DNA-derived materials in therapy and diagnosis poses a new challenge for biological standardization, that of developing reference preparations appropriate for both the native and recombinant products. Here we report the results of an international collaborative study that was carried out under the auspices of WHO to assess the suitability of a preparation of recombinant thyroid-stimulating hormone (rTSH; 94/674) to serve as a potential standard for the calibration of diagnostic immunoassays compared with the International Reference Preparation (IRP) for human TSH (80/558). Methods: Coded samples were provided to the 33 laboratories in the study, and participants were asked to perform TSH assays currently in use in their laboratories. Twenty-eight laboratories contributed 93 immunoassays in 41 different method-laboratory combinations, and an additional 5 laboratories contributed bioassay data. All data were analyzed centrally at the National Institute for Biological Standards and Control. Results: The results obtained in different laboratories and with different assay systems revealed significant variability between estimates of rTSH relative to the IRP. These ranged from 5.51 mIU (95% limits, 3.95–7.67 mIU) per ampoule by RIA to 7.15 mIU (95% limits, 6.7–7.63 mIU) per ampoule by immunofluorometric assay. However, the results showed that the assignment of a value of 6.70 mIU per ampoule of 94/674 would give reasonable continuity with the IRP in many assay systems. Conclusions: The preparation was established as the First WHO Reference Reagent for TSH, human, recombinant, to provide a means of validating assay performance and to maintain continuity with the IRP without compromising clinical data.


1994 ◽  
Vol 72 (9) ◽  
pp. 1066-1074 ◽  
Author(s):  
Melvin J. Fregly ◽  
Fabian Rossi ◽  
J. Robert Cade

The systolic blood pressures of two groups of rats that were exposed to cold (5 °C) for 4 weeks were elevated significantly above that of warm-acclimated controls maintained at 24 °C. At this time these groups were given the antithyroid drug aminotriazole in their food at 0.3 g/kg. At the same time, one group was given 15.8 μg thyroxine (T4)/kg body mass per day, while the second received 31.6. The doses were chosen as replacement (15.8 μg/kg) and twice replacement (31.8 μg/kg) for the rats. The results of the study revealed that both groups receiving aminotriazole and T4 had reductions in blood pressure within 1 week of initiation of treatment. Blood pressures reached control level after 5 weeks. Cardiac hypertrophy accompanying cold-induced hypertension was reduced with the lower dose of T4 and prevented with the higher dose. Serum concentrations of T4 and triiodothyronine (T3) in the two treated groups were reduced, while serum thyroid-stimulating hormone concentration and thyroid mass were increased above that of the warm-acclimated control group. This suggests that the rats were hypothyroid relative to the warm-acclimated control group. However, the treated rats grew at the same rate as nontreated, cold-exposed controls and had similar food and water intakes, a similar dipsogenic response to acute administration of isoproterenol, and similar colonic temperatures. These measurements suggest that the rats were not functionally hypothyroid. Nevertheless, the results suggest that a paradigm in which the secretory ability of the thyroid gland is blocked, and T4 is returned at a constant, albeit suboptimal, level, reduced blood pressure and cardiac hypertrophy in cold-exposed rats. Hence, the increased turnover of thyroid hormones that characteristically accompanies exposure to cold plays a role in these changes. These studies also indicate that an increase in the rate of secretion of T4 is not required for survival in cold air.Key words: cold-induced hypertension, thyroxine, triiodothyronine, thyroid-stimulating hormone, aminotriazole, antithyroid drug, blood pressure, cardiac hypertrophy, catecholamines, norepinephrine, epinephrine, dopamine.


1981 ◽  
Vol 97 (3) ◽  
pp. 361-368 ◽  
Author(s):  
J. Salmerón De Diego ◽  
C. Alonso Rodriguez ◽  
A. Salazar Orlando ◽  
P. Sanchez Garcia Cervigon ◽  
E. Caviola Mutazzi ◽  
...  

Abstract. A 74 year old woman was found to have elevated serum thyroid-stimulating hormone (TSH) levels and elevated serum thyroid hormone levels, with clinical euthyroidism. There was no evidence of a pituitary tumour. TSH levels increased substantially during methimazole therapy. Administration of dexamethasone was followed by a prompt fall in serum TSH levels. Triiodothyronine (T3) was administered over a period of 20 days in doses from 25 μg to as much as 100 μg daily causing a rise in serum T3 above 700 ng/100 ml, a decline of T4 and a blunting of the response to thyrotrophinreleasing hormone (TRH), with normal metabolic responses (pulse rate, photomotogram, cholesterol). These results suggest that the patient's disorder is due to partial target organ resistance to thyroid hormones.


1996 ◽  
Vol 17 (1) ◽  
pp. 39-45 ◽  
Author(s):  
Anna Capaldo ◽  
Vincenza Laforgia ◽  
Rosaria Sciarrillo ◽  
Antimo Cavagnuolo

AbstractInsulin was administered to Podarcis sicula in winter, when the thyroid gland is inhibited. The activity of the thyroid increased, plasma concentrations of thyroid hormones and hepatic 5'-monodeiodinase activity (MDA) increased, and thyroid stimulating hormone (TSH) concentrations fell to undetectable values. This result confirms the influence of insulin on the activity of the thyroid gland in the lizard species studied. The mechanisms are still unclear, although there is evidence which leads us to believe that insulin is directly responsible for thyroid activation.


Sign in / Sign up

Export Citation Format

Share Document